Scandion Oncology - CORIST part 3 begins enrolment
Scandion Oncology has announced that the first patient in part 3 of the Phase II CORIST trial has been dosed. The CORIST development programme is investigating the use of the company’s chemotherapy add-on, SCO-101, in combination with FOLFIRI in metastatic colorectal cancer (mCRC). Importantly, part 3 will expand the patient population to include those harbouring RAS mutations (c 50% of patients) and will investigate optimised dosing schedules based on findings from CORIST part 2. The initiation of part 3 is on schedule with management’s communicated timelines and is expected to report top-line results in Q323. After part 2 top-line results failed to provide proof-of-concept for the SCO-101/FOLFIRI combination, we believe secondary efficacy endpoints from part 3 will be important in establishing SCO-101’s clinical utility. We value Scandion Oncology at SEK279.0m or SEK6.9 per share.Scandion Oncology A/S. Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.